Vyant Bio (VYNT) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'CGIX	'
Entity Registrant Name	'CANCER GENETICS, INC	'
Entity Central Index Key	'0001349929	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	9,696,658

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$37,417,742	$49,459,564
Accounts receivable, net of allowance for doubtful accounts of $36,000	2,056,266	1,567,039
Other current assets	1,219,205	864,616
Total current assets	40,693,213	51,891,219
FIXED ASSETS, net of accumulated depreciation	1,476,247	1,264,624
OTHER ASSETS	'	'
Security deposits	1,564	1,564
Restricted cash	6,300,000	300,000
Loan guarantee and financing fees, net of accumulated amortization of $517,500 in 2013	0	310,500
Patents	450,934	401,709
Investment in joint venture	677,464	987,657
Total other assets	7,429,962	2,001,430
Total Assets	49,599,422	55,157,273
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	2,283,032	2,346,240
Obligations under capital leases, current portion	57,606	51,400
Deferred revenue	31,833	199,560
Notes payable, current portion	0	22,298
Line of credit	0	6,000,000
Total current liabilities	2,372,471	8,619,498
Obligations under capital leases	331,636	309,777
Deferred rent payable	157,978	170,789
Line of credit	6,000,000	0
Warrant liability	274,000	594,000
Total liabilities	9,136,085	9,694,064
STOCKHOLDERS’ EQUITY	'	'
Preferred stock, authorized 9,764,000 shares, $0.0001 par value, none issued	0	0
Common stock, authorized 100,000,000 shares, $0.0001 par value, 9,464,709 and 9,275,384 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	947	927
Additional paid-in capital	108,459,567	106,786,862
Accumulated deficit	-67,997,177	-61,324,580
Total Stockholders’ Equity	40,463,337	45,463,209
Total Liabilities and Stockholders’ Equity	$49,599,422	$55,157,273

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts receivables	$36,000	$36,000
Loan guarantee and financing fees, accumulated amortization	'	$517,500
Preferred stock, shares authorized (in shares)	9,764,000	9,764,000
Preferred stock, par value (usd per share)	$0.00	$0.00
Preferred Stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, par value (usd per share)	$0.00	$0.00
Common stock, shares issued (in shares)	9,464,709	9,275,384
Common stock, shares outstanding (in shares)	9,464,709	9,275,384

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$1,511,670	$1,831,649	$2,942,045	$3,050,316
Cost of revenues	1,503,095	1,279,274	2,793,157	2,349,294
Gross profit	8,575	552,375	148,888	701,022
Operating expenses:	'	'	'	'
Research and development	1,105,773	455,570	1,702,544	950,597
General and administrative	2,395,462	1,384,123	5,126,866	2,961,374
Sales and marketing	918,457	446,468	1,667,436	831,955
Total operating expenses	4,419,692	2,286,161	8,496,846	4,743,926
Loss from operations	-4,411,117	-1,733,786	-8,347,958	-4,042,904
Other income (expense):	'	'	'	'
Interest expense	-30,744	-389,319	-371,921	-1,683,308
Interest income	16,157	744	38,341	1,354
Debt conversion costs	0	-6,849,830	0	-6,849,830
Change in fair value of warrant liability	239,000	-170,000	195,000	5,129,000
Total other income (expense)	224,413	-7,408,405	-138,580	-3,402,784
Income (loss) before income taxes	-4,186,704	-9,142,191	-8,486,538	-7,445,688
Income tax provision (benefit)	0	0	-1,813,941	-663,900
Net income (loss)	($4,186,704)	($9,142,191)	($6,672,597)	($6,781,788)
Basic net income (loss) per share (usd per share)	($0.45)	($2.29)	($0.72)	($2.54)
Diluted net loss per share (usd per share)	($0.47)	($2.29)	($0.74)	($4.46)
Basic Weighted Average Shares Outstanding (in shares)	9,302,737	3,985,663	9,289,624	2,667,799
Diluted Weighted Average Shares Outstanding (in shares)	9,318,634	3,985,663	9,314,155	2,667,799

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net income (loss)	($6,672,597)	($6,781,788)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation	214,450	151,066
Amortization	13,431	7,615
Equity-based consulting and compensation expenses	1,293,705	215,219
Equity-based research and development expenses	0	74,650
Change in fair value of warrant liability	-195,000	-5,129,000
Amortization of loan guarantee and financing fees	310,500	612,605
Accretion of discount on debt	0	581,193
Deferred rent	-12,811	3,245
Loss in equity method investment	310,193	0
Deferred initial public offering costs expensed	0	617,706
Write-off of debt conversion costs	0	6,849,830
Change in working capital components:	'	'
Accounts receivable	-489,227	-412,696
Other current assets	-354,589	-219,636
Accounts payable, accrued expenses and deferred revenue	-230,935	-335,837
Net cash (used in) operating activities	-5,812,880	-3,765,828
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchase of fixed assets	-385,151	-42,576
Increase in restricted cash	-6,000,000	-50,000
Patent costs	-62,656	-31,679
Net cash (used in) investing activities	-6,447,807	-124,255
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Principal payments on capital lease obligations	-12,857	-8,437
Proceeds from initial public offering of common stock, net of offering costs	0	5,054,514
Payment of equity issuance costs for secondary public offering	0	-92,941
Proceeds from warrant exercises	178,102	96,000
Proceeds from option exercises	75,918	'
Principal payments on notes payable	-22,298	-38,151
Net cash provided by financing activities	218,865	5,010,985
Net (decrease) in cash and cash equivalents	-12,041,822	1,120,902
CASH AND CASH EQUIVALENTS	'	'
Beginning	49,459,564	819,906
Ending	37,417,742	1,940,808
SUPPLEMENTAL CASH FLOW DISCLOSURE	'	'
Cash paid for interest	61,421	489,509
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES	'	'
Warrants issued for financing fees	0	47,000
Accrued offering costs	0	50,000
Fixed assets acquired through capital lease arrangements	40,922	'
Cashless exercise of derivative warrants	125,000	'
IPO costs discounted	0	733,250
Accrued expenses reclassified as derivative warrant liability	0	221,000
Retirement of treasury stock	0	17,442
Conversion of notes payable, lines of credit and accrued interest to common stock	0	9,364,300
Conversion of preferred stock to common stock	'	241
Reclassification of derivative warrants	0	7,170,000
Reclassification of deferred offering costs to additional paid in capital	$0	$1,992,333

Description_of_Business_Basis_

Description of Business, Basis of Presentation, Acquisition, Pending Acquisition, Public Offerings and Reverse Stock Splits	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of Business, Basis of Presentation, Acquisition, Pending Acquisition, Public Offerings and Reverse Stock Splits	'
	Description of Business, Basis of Presentation, Acquisition, Pending Acquisition, Public Offerings and Reverse Stock Splits
	We are a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer (theranosis). Our proprietary tests target cancers where prognosis information is critical and where predicting treatment outcomes using currently available techniques is limited. These cancers include hematological, urogenital and HPV-associated cancers. We seek to provide our tests and services to oncologists and pathologists at hospitals, cancer centers and physician offices, as well as to biopharmaceutical companies and clinical research organizations for their clinical trials.
	Acquisition - Gentris Corporation
	On July 15, 2014, we entered into an Asset Purchase Agreement (the “Agreement”) to purchase substantially all of the assets of Gentris Corporation, a Delaware corporation (“Gentris”), with its principal place of business in North Carolina. The transaction closed on July 16, 2014.
	Gentris provides genomic testing and pharmacogenomics services to half of the top ten biopharma companies globally and has participated and performed genomic analysis for over 1,000 clinical trials. Gentris has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China in state-of-the-art GLP, CLIA and FDA-compliant facilities. It is contemplated that Gentris will become fully integrated with our operations. Gentris has 39 employees and 28,000 square feet of laboratory space.
	The initial acquisition price of Gentris was (i) $3.25 million in cash (subject to potential minor reduction based on obligations of Gentris due at closing), plus (ii) a number of our shares of common stock equal to $1.50 million divided by the volume weighted average price of our common stock on The Nasdaq Capital Market for the five days immediately preceding the closing date of this transaction, plus (iii) a potential earn-out of up to $1.50 million over the next calendar year, which earn-out is payable in cash or shares of our common stock at our option, and is based upon a formula that provides for an additional amount starting at $300,000 for revenues of $4.75 million, up to an additional amount of $1.5 million for revenues of $8.55 million, plus (iv) a potential payment to be made in connection with the termination of Merck’s biorepository relationship with Gentris, based upon exit fees to be received by Gentris from Merck. The volume weighted average price of our common stock on The Nasdaq Capital Market for the five days preceding closing was $10.1459 per share, causing the number of shares of common stock issued in the acquisition to amount to an aggregate of 147,843 shares. The source of the $3.25 million of cash was the Company’s working capital. The transaction was treated as an asset purchase. We incurred a finder's fee of $147,500 related to the transaction, $125,000 of which was paid in July, 2014.
	As of June 30, 2014, we had a loan receivable from Gentris in the amount of $300,000 which is included in other assets in the Consolidated Balance Sheet . The loan was made on May 23, 2014 and bore interest at 4%. The loan was converted to an advance on the purchase price at time of close.
	Pending Acquisition - Bioserve India
	On May 12, 2014, we entered into two related agreements whereby we agreed to acquire BioServe BioTechnologies (India) Private Limited, an Indian corporation (“BioServe”).
	BioServe is a leading genomic service and next-generation sequencing company founded in 2002 serving both the research and clinical markets and based in Hyderabad, India. It has approximately 26 employees. If the transaction is consummated, we believe we will be able to access the Indian healthcare market. The acquisition provides the Company with an infrastructure in India for developing lower cost manufacturing of probes and kits including probes and kits used for our proprietary FHACT test, a center for remote genetic analysis of US cases at lower cost and access to one of the fastest-growing molecular and clinical diagnostic markets in the world. BioServe will continue to serve biotechnology and biopharmaceutical companies, diagnostic companies and research hospitals, including those owned or operated by the Indian government, as well as seek to expand its customer base.
	The parties to the first agreement (the “India Agreement”) are the Company, Ramakishna V. Modali (the current general manager of BioServe, “Modali”), Ventureast Trustee Company Pvt Ltd and affiliates, its principal shareholder (“Ventureast”), and certain other shareholders residing in India all of whom in the aggregate own approximately 74% of BioServe. The parties to the second share purchase agreement (the “US Agreement”) are the Company and BioServe Biotechnologies LTD, a Maryland corporation and an affiliate of BioServe which owns approximately 15% of BioServe, with the majority of the other outstanding shares held by the BioServe Employee Stock Ownership Plan which will remain in place. The aggregate purchase price is approximately $1.9 million payable to the different shareholders of BioServe as follows: (i) Ventureast will receive a payment equivalent to the cash value of 84,278 shares of the Company’s common stock at the time of payment, payable in 30 months or sooner if the Company effects a public offering of its common stock prior to that time, (ii) approximately $100,000 is payable in cash to various other shareholders, and (iii) approximately 8,687 shares will be issued to various other shareholders under the US Agreement. The Company will also assume approximately $170,000 in indebtedness. The Company formed a subsidiary in India to which it assigned its rights to purchase shares under the India Agreement. Certain payments to the BioServe shareholders will be subject to set-off in the event of claims for indemnification for any breaches of any representations or warranties in the agreement.
	As a condition of closing Mr. Modali has agreed to be employed by the Company. To induce him to enter into this agreement, he will receive a restricted stock grant of approximately 22,683 shares of the Company’s common stock that will be fully vested upon issuance. The shares will be subject to customary sales restrictions under United States Securities regulations and subject to set-off as a part of the warranties in the agreement.
	The consummation of the transactions is subject to various conditions, including certain filings to be made and approvals received in India; the absence of any material adverse effect with respect to BioServe; the absence of any order or law preventing consummation of the transactions; and other legal and regulatory requirements.
	Either party may terminate the agreements and the transactions contemplated thereby if the Closing has not occurred by the end of August, 2014. The Company anticipates closing in the third quarter of 2014.
	Public Offerings and Reverse Stock Splits
	In April 2013, we sold shares of our common stock in an initial public offering (“IPO”). Additionally, we sold shares of our common stock in public offerings in August 2013 and in October 2013. Refer to Note 6 for further discussion of these offerings.
	On February 8, 2013, we filed a charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2 reverse stock split of our common stock. On March 1, 2013, we filed another charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2.5 reverse stock split of our common stock. All shares and per share information referenced throughout the consolidated financial statements reflect both reverse splits.

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Significant Accounting Policies
	Basis of presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions for interim reporting as they are prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2013 that are included in our Form 10-K filed with the SEC on March 28, 2014. The consolidated balance sheet as of December 31, 2013, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2014.
	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) cash collections from our customers (ii) cash received from sales of state net operating loss carryforwards, and; (iii) grants from the National Institutes of Health.
	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiary, Cancer Genetics Italia S.r.l (“CGI Italia”). CGI Italia manufactures DNA probes. CGI Italia had approximately $470,000 and $398,000 in total assets at June 30, 2014 and December 31, 2013, respectively, and approximately $96,000 and $44,000 in total revenue for the six months ended June 30, 2014 and 2013, respectively. All significant intercompany account balances and transactions have been eliminated in consolidation.
	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments and assumptions used to value stock options and warrants. Actual results could differ from those estimates.
	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
	Restricted cash: Represents cash held at financial institutions which we may not withdraw and which collateralizes certain of our financial commitments. All of our restricted cash is invested in interest bearing certificates of deposit. Our restricted cash collateralizes a fully-utilized $6.0 million line of credit with Wells Fargo Bank and a $300,000 letter of credit in favor of our landlord, pursuant to the terms of the lease for our Rutherford facility.
	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For direct bill customers (including clinical trials customers), revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. Until then, we recognize revenue equal to the amount of cash received. Sales of probes are recorded on the shipping date. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows. The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Note 9). Following the IPO in April 2013 and until our shares listed on the NASDAQ Capital Market in August 2013, we used the closing price of our shares on the OTC Bulletin Board. Following the listing of our shares on the NASDAQ Capital Market in August 2013, we used the closing price on the NASDAQ Capital Market.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated balance sheets and we have not recognized interest and/or penalties in the consolidated statements of operations.
	In January 2013, we executed a sale of $8,018,107 of gross State of New Jersey NOL carryforwards, resulting in the receipt of $663,900. The proceeds were recorded as an income tax benefit in January, 2013. In January 2014, we executed a sale of $22,301,643 of gross state NOL carryforwards resulting in the receipt of $1,813,941. The Company transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there were no intangible asset impairments during the periods reported. Accumulated amortization of patents as of June 30, 2014 and December 31, 2013 was approximately $69,000 and $56,000, respectively.
	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of June 30, 2014 and December 31, 2013, we have an accrued liability of $300,000 related to the issuance of Series B preferred stock.
	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 7.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurements under the fair value hierarchy. The fair values of our notes payable, line of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities is described in Note 9.
	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was approximately $298,000 and $0 for the three months ended June 30, 2014 and 2013, respectively and $310,000 and $0 for the six months ended June 30, 2014 and 2013, respectively, and is included in Research and development expense on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $0 and $24,000 at June 30, 2014 and December 31, 2013, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 11.
	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
	Recent Accounting Pronouncements: In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for the Company in the first quarter of fiscal year 2017.  The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on the consolidated financial statements.
	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.
	Basic net loss and diluted net loss per share data were computed as follows:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Net income (loss) for basic earnings per share	$	(4,186,704	)		$	(9,142,191	)	$	(6,672,597	)	$	(6,781,788	)
	Change in fair value of warrant liability	239,000				—			195,000			5,129,000
	Net (loss) for diluted earnings per share	$	(4,425,704	)		$	(9,142,191	)	$	(6,867,597	)	$	(11,910,788	)
	Denominator:
	Weighted-average basic common shares outstanding	9,302,737				3,985,663			9,289,624			2,667,799
	Assumed conversion of dilutive securities:
	Common stock purchase warrants	15,897				—			24,531			—
	Potentially dilutive common shares	15,897				—			24,531			—
	Denominator for diluted earnings per share – adjusted weighted-average shares	9,318,634				3,985,663			9,314,155			2,667,799
	Basic net income (loss) per share	$	(0.45	)		$	(2.29	)	$	(0.72	)	$	(2.54	)
	Diluted net loss per share	$	(0.47	)		$	(2.29	)	$	(0.74	)	$	(4.46	)
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Common stock purchase warrants	1,661,696			1,926,477			1,661,696		1,926,477
	Stock options	1,277,947			507,610			1,277,947		507,610
	Restricted shares of common stock	122,500			—			122,500		—
		3,062,143			2,434,087			3,062,143		2,434,087

Revenue_and_Accounts_Receivabl

Revenue and Accounts Receivable	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Revenue and Accounts Receivable	'
	Revenue and Accounts Receivable
	Revenue by payor type for the three and six months ended June 30, 2014 and 2013 is comprised of the following:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014	2013
	Medicare	$	268,171		$	151,052		518,292	408,115
	Direct bill (including clinical trials)	850,740			1,226,852			1,719,998	1,738,199
	Insurance carrier and all others	392,759			453,745			703,755	904,002
		$	1,511,670		$	1,831,649		2,942,045	3,050,316
	Accounts receivable by payor type at June 30, 2014 and December 31, 2013 consists of the following:
		June 30,			December 31,
		2014			2013
	Medicare	$	616,417		$	408,856
	Direct bill (including clinical trials)	863,732			628,830
	Insurance carrier and all others	612,117			565,353
	Allowance for doubtful accounts	(36,000		)	(36,000		)
		$	2,056,266		$	1,567,039
	We have historically derived a significant portion of our revenue from a limited number of test ordering sites. The test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and clinical trial clients. Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being enrolled.
	The top five test ordering sites during the three months ended June 30, 2014 and 2013 accounted for 51% and 74% respectively, of our clinical testing volumes, with 44% and 23% respectively, of the volume coming from community hospitals. During the three months ended June 30, 2014, there was one site which accounted for approximately 10% or more of our revenue. A clinical trial client accounted for approximately 23% of our revenue. During the three months ended June 30, 2013, there was one site which accounted for approximately 10% or more of our revenue. A clinical trial client accounted for approximately 50% of our revenue.
	The top five test ordering sites during the six months ended June 30, 2014 and 2013 accounted for 57% and 69% respectively, of our clinical testing volumes, with 38% and 27% respectively, of the volume coming from community hospitals. During the six months ended June 30, 2014, there was one site which accounted for approximately 10% or more of our revenue. A clinical trial client accounted for approximately 28% of our revenue. During the six months ended June 30, 2013, there was one site which accounted for approximately 10% or more of our revenue. A clinical trial client accounted for approximately 38% of our revenue. While we have agreements with our clinical trials clients, volumes from these clients is subject to the progression and continuation of the trials as determined by the client which can impact testing volume. We generally do not have formal written agreements with other testing sites and, as a result, we may lose these significant test ordering sites at any time.

Notes_Payable_and_Line_of_Cred

Notes Payable and Line of Credit	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable and Line of Credit	'
	Notes Payable and Line of Credit
	Below is a summary of our short-term and long-term debt obligations as of June 30, 2014 and December 31, 2013:
		June 30,		December 31,
		2014		2013
	Secured Note Payable, short-term	$	—	$	22,298
	Notes Payable, Current Portion	$	—	$	22,298
	Line of Credit, Principal Balance	$	—	$	6,000,000
	Line of Credit, Current Portion	$	—	$	6,000,000
	Lines of Credit, Long-Term	$	6,000,000	$	—
	Business Line of Credit — Wells Fargo
	At December 31, 2013 and June 30, 2014, we had fully utilized a line of credit (“Line”) with Wells Fargo Bank which provided for maximum borrowings of $6 million. Interest on the Line was due monthly equal to 1.75% above the Daily One Month LIBOR rate (2.0% at March 31, 2014). The Line required the repayment of principal, and any unpaid interest, in a single payment due upon maturity. The Line matured April 1, 2014, was guaranteed by John Pappajohn, our Chairman of the Board of Directors and significant shareholder, and was collateralized by a first lien on all of our assets including the assignment of our approved and pending patent applications.
	On April 1, 2014 we entered into a credit agreement (the “Credit Agreement”) and re-negotiated the terms of the Line with Wells Fargo Bank. Under the terms of the Credit Agreement we maintain the Line with maximum borrowings of $6 million which have been fully drawn. The Line has been extended through April 1, 2016 at a rate of interest equal to LIBOR plus 1.75% (2.0% at April 1, 2014). The facility requires monthly interest payments. The pledge of all of our assets and intellectual property, as well as the guarantee by Mr. Pappajohn, was released and instead we restricted $6.0 million in cash, which is invested in an interest bearing certificate of deposit, as collateral. Additionally, we are required to maintain limits on capital spending and are restricted as to the amount we may pledge as collateral for additional borrowings from any source. The Credit Agreement requires the repayment of principal, and any unpaid interest, in a single payment due upon maturity. As result of the extension of the maturity date and the transfer of cash to Wells Fargo as collateral, we have presented the line of credit as a long-term liability and the cash collateral as restricted cash at June 30, 2014. The cash will remain restricted until such time as the Line is repaid.
	Secured Note Payable
	On September 25, 2012, we entered into a note payable secured by lab equipment due March 25, 2014. The note required monthly payments of principal and interest at 18% per annum. At December 31, 2013, $22,298 was outstanding under the note. On February 21, 2014, the note was paid off prior to its contractual due date.

Letter_of_Credit

Letter of Credit	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Letter of Credit	'
	Letter of Credit
	During 2013 we restricted an additional $50,000 in cash and secured a $300,000 letter of credit in favor of our landlord pursuant to the terms of the lease for our Rutherford facility. At June 30, 2014 the letter of credit was fully secured by the restricted cash disclosed on our Consolidated Balance Sheet.

Capital_Stock

Capital Stock	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Capital Stock	'
	Capital Stock
	IPO
	On April 10, 2013, we completed our IPO in which we issued and sold 690,000 shares of common stock (including the underwriter’s overallotment of 90,000 shares) at a public offering price of $10.00 per share, resulting in gross proceeds of $6.9 million (net proceeds of $5 million). Upon closing of the IPO, all outstanding shares of Series A preferred stock were converted into 376,525 shares of common stock, and all outstanding shares of Series B preferred stock were converted into 910,800 shares of common stock. Also upon closing of the IPO, $9.6 million of debt converted into 963,430 shares of common stock. Concurrent with the IPO, certain derivative warrants with a fair value of $7.2 million were reclassified into equity due to the lapsing of anti-dilution provisions in the warrants. Also concurrent with the IPO, we issued 2,000 shares of common stock to Cleveland Clinic pursuant to our license agreement with Cleveland Clinic.
	Secondary Offering
	On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million ($13.3 million of net proceeds after offering expenses and underwriting discounts). We used $3.5 million of the proceeds to repay certain indebtedness which was due on August 15, 2013. On September 5, 2013, we sold 105,000 additional common shares pursuant to the underwriter’s partial exercise of the over-allotment option which resulted in gross proceeds of $1.1 million ($947,000 of net proceeds after offering expenses and underwriting discounts). All references to the sales of common stock mentioned in this paragraph are referred to as the “Secondary Offering.”
	Follow-On Offering
	On October 28, 2013, we sold 3,286,700 shares of common stock (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million). All references to the sales of common stock mentioned in this paragraph are referred to as the “Follow-On Offering.”
	Preferred Stock
	We are currently authorized to issue up to 9,764,000 shares of preferred stock.

Stock_Option_Plans

Stock Option Plans	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Option Plans	'
	Stock Option Plans
	We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years.
	The Board of Directors adopted the 2011 Plan on June 30, 2011 and reserved 350,000 shares of common stock for issuance under the 2011 Plan. On May 22, 2014, the stockholders voted to increase the number of shares reserved by the plan to 2,000,000 shares of common stock under several types of equity awards including stock options, stock appreciation rights, restricted stock awards and other awards defined in the 2011 Plan.
	The Board of Directors adopted the 2008 Plan on April 29, 2008 and reserved 251,475 shares of common stock for issuance under the plan. On April 1, 2010, the stockholders voted to increase the number of shares reserved by the plan to 550,000. We are authorized to issue incentive stock options or non-statutory stock options to eligible participants.
	We have also issued 48,000 options outside of the Stock Option Plans.
	At June 30, 2014, 1,099,688 shares remain available for future awards under the 2011 Plan and 30,059 shares remain available for future awards under the 2008 Plan.
	As of June 30, 2014, no stock appreciation rights and 122,500 shares of restricted stock have been awarded under the Stock Option Plans.
	Prior to our IPO in April 2013, the Board of Directors authorized an offer to certain employee and non-employee options holders on the following terms: those holding stock options with a strike price of $25.00 or more had the opportunity to exchange their options for 60% of the number of options currently held with an exercise price equal to the IPO price, which was $10.00 per share, and those holding stock options with a strike price of $12.50 had the opportunity to exchange their options for 80% of the number of options currently held with an exercise price equal to the IPO price which was $10.00 per share. On April 5, 2013, our initial public offering became effective and 336,300 options with exercise prices ranging from $12.50 to $33.80 were exchanged for 242,070 options with an exercise price of $10.00. The exchange of the options did not result in the recognition of incremental compensation cost. In addition, 53,500 options which were approved to be issued and priced at the IPO price were issued to employees with an exercise price of $10.00 per share.
	A summary of employee and nonemployee stock option activity for year ended December 31, 2013 and the six months ended June 30, 2014 is as follows:
		Options Outstanding						Weighted-		Aggregate
								Average		Intrinsic
								Remaining		Value
								Contractual
		Number of		Weighted-				Term (in years)
		Shares		Average
				Exercise
				Price
	Outstanding January 1, 2013	553,340		$	12.76			7.13		$	1,142,432
	Granted	426,762		14.57
	Exercised	(164	)	10
	Cancelled or expired	(106,396	)	20.46
	Outstanding December 31, 2013	873,542		$	10.83			7.75		$	3,138,539
	Granted	465,000		15.09
	Exercised	(29,442	)	6.65
	Cancelled or expired	(31,153	)	9.34
	Outstanding June 30, 2014	1,277,947		$	12.52			7.94		$	1,563,786
	Exercisable June 30, 2014	457,489		$	8.46			5.46		$	1,485,305
	Aggregate intrinsic value represents the difference between the estimated fair value of our common stock and the exercise price of outstanding, in-the-money options. The fair value of our common stock was $11.30 at June 30, 2014 and $13.78 at December 31, 2013, based on the closing price on the NASDAQ Capital Market.
	As of June 30, 2014, total unrecognized compensation cost related to non-vested stock options and restricted stock granted to employees was $6,196,957 which we expect to recognize over the next 3.51 years.
	As of June 30, 2014, total unrecognized compensation cost related to non-vested stock options granted to non-employees was $1,383,611 which we expect to recognize over the next 3.5 years. The estimate of unrecognized nonemployee compensation is based on the fair value of the non-vested options as of June 30, 2014.
	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of June 30, 2014 as follows:
		Options Outstanding								Options Vested and Exercisable
	Exercise Price	Number of		Weighted-				Weighted-		Number of		Weighted-
		Shares		Average				Average		Shares		Average
		Outstanding		Exercise				Remaining				Exercise Price
				Price				Contract
								Life (in
								Years)
	4	145,000		$	4			4.72		145,000		$	4
	4.8	31,555		4.8				5.56		28,207		4.8
	10	276,180		10				5.65		227,330		10
	11.70 - 11.75	80,600		11.71				9.83		1,306		11.75
	12.50 - 14.18	118,700		13.86				9.51		1,140		12.54
	15.39	335,912		15.39				9.01		37,506		15.39
	15.89	200,000		15.89				9.56		12,500		15.89
	17.38	90,000		17.38				9.72		4,500		17.38
	Total	1,277,947		$	12.52			7.94		457,489		$	8.46
	The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the fair value of our common stock prior to our IPO (see Note 9), the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. We also estimate forfeitures of unvested stock options. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, and volatility is based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants and the plan design which has monthly vesting after an initial cliff vesting period.
	In 2010, we issued an aggregate of 80,000 options to non-employees with an exercise price of $25.00. As described above, on April 5, 2013, these options were exchanged for 48,000 options with an exercise price of $10.00. In October 2013, we issued 10,000 options to a non-employee with an exercise price of $15.39. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014		2013			2014		2013
	Volatility	71.6	%	76.21	%		72.13	%	76.04	%
	Risk free interest rate	2.53	%	1.23	%		2.63	%	1.24	%
	Dividend yield	0	%	0	%		0	%	0	%
	Term (years)	9.28		7.46			9.4		7.58
	The following table presents the effects of stock-based compensation related to stock option awards to employees and nonemployees on our Statement of Operations during the periods presented:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014			2013				2014			2013
	Cost of revenues	$	20,496		$	11,967			$	40,908		$	14,179
	Research and development	143,069			35,962				157,171			90,798
	General and administrative	552,713			94,112				1,021,568			152,267
	Sales and marketing	47,304			30,693				74,058			32,625
	Total stock-based compensation	$	763,582		$	172,734			$	1,293,705		$	289,869

Warrants

Warrants	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Warrants	'
	Warrants
	We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price (share adjustment feature). These warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount, additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. As of June 30, 2014 all warrants with a share adjustment feature have either expired or have been exercised.
	In January 2014, the Company received $950 from a warrant holder who exercised warrants to purchase 95 shares of common stock at $10.00 per share. In February 2014 a warrant holder exercised warrants to purchase 3,320 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 1,661 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 1,659 shares. In March 2014 a warrant holder exercised warrants to purchase 12,500 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 7,230 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 5,270 shares. In June 2014, the company received $177,154 from Mr. Pappajohn who exercised warrants to purchase 44,288 shares of common stock at an exercise price of $4.00 per share.
	Subsequent Events
	In July 2014, warrant holders exercised warrants to purchase 130,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method whereby 45,894 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 84,106 shares.
	The following table summarizes the warrant activity for the six months ended June 30, 2014:
	Issued With / For	Exercise			Warrants	2014 Warrants Exercised		Warrants Outstanding June 30, 2014
		Price			Outstanding
					January 1,
					2014
	Non-Derivative Warrants:
	Financing	$	10		243,334	—		243,334
	Financing	15			436,079	—		436,079
	Debt Guarantee	4			174,288	(44,288	)	130,000
	Debt Guarantee	10			237,500	—		237,500
	Debt Guarantee	15			585,645	—		585,645
	Consulting	10			29,138	—		29,138
		12.38		C	1,705,984	(44,288	)	1,661,696
	Derivative Warrants:
	Financing	10		B	60,000	—		60,000
	Debt Guarantee	10		A	12,500	(12,500	)	—
	Series B Pref. Stock	10		B	18,430	(3,415	)	15,015
	Consulting	10		B	200	—		200
		10		C	91,130	(15,915	)	75,215
		$	12.28	C	1,797,114	(60,203	)	1,736,911
	A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 9.
	B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 9.
	C	Weighted average exercise prices are as of June 30, 2014.

Fair_Value_of_Warrants

Fair Value of Warrants	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Warrants	'
	Fair Value of Warrants
	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the six months ended June 30, 2014 and 2013 and at June 30, 2014, December 31, 2013 and April 5, 2013 (IPO valuation date). In computing the fair value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the applicable warrants. Such adjustments were only applicable to the six months ended June 30, 2013 due to the relative price of the warrants and the assumed Company stock price.
	Issued with Debt Guarantee	Exercised During the Six Months Ended June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	10		$	10		$	13.56
	Expected life (years)	0.6			0.83			2.42
	Expected volatility	49.01		%	57.33		%	66.37		%
	Risk-free interest rate	0.08		%	0.13		%	0.32		%
	Expected dividend yield	—		%	—		%	—		%
	Issued with Series B Preferred Shares	Exercised During the Six Months Ended June 30, 2014			As of June 30, 2014			As of December 31, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.72			1.42			1.92
	Expected volatility	46.6		%	48.5		%	59.26		%
	Risk-free interest rate	0.33		%	0.11		%	0.38		%
	Expected dividend yield	—		%	—		%	—		%
	Issued for Consulting	As of June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.65			2.14			2.33
	Expected volatility	47.04		%	63.63		%	63.2		%
	Risk-free interest rate	0.44		%	0.38		%	0.27		%
	Expected dividend yield	—		%	—		%	—		%
	Issued with Financing	Exercised During the Three Months Ended June 30, 2014			As of June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	13.34		$	10		$	10		$	13.21
	Expected life (years)	9.78			1.75			2.25			8.3
	Expected volatility	74.7		%	47.05		%	64.4		%	73.22		%
	Risk-free interest rate	1.95		%	0.44		%	0.38		%	1.44		%
	Expected dividend yield	—		%	—		%	—		%	—		%
	The assumed Company stock price used in computing the fair value of warrants exercised during the six months ended June 30, 2014 was $15.20 – $19.86 and for the fair value of warrants issued during the six months ended June 30, 2014, the assumed range of Company stock prices used was $9.60 – $9.96. In determining the fair value of warrants issued at each reporting date, the Company stock price was $11.30 at June 30, 2014 and $13.78 at December 31, 2013 based on the closing price on the NASDAQ Capital Market.
	The following table summarizes the derivative warrant activity subject to fair value accounting for the six months ended June 30, 2014:
	Issued with/for	Fair value of			Fair value			Change in			Fair value of
		warrants			of warrants			fair value			warrants
		outstanding as of			exercised			of warrants			outstanding as of
		December 31, 2013									30-Jun-14
	Series B Preferred Stock	$	117,000		$	(38,000	)	$	(28,000	)	$	51,000
	Debt Guarantee	64,000			(87,000		)	23,000			—
	Consulting	1,000			—			—			1,000
	Financing	412,000			—			(190,000		)	222,000
		$	594,000		$	(125,000	)	$	(195,000	)	$	274,000

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
	Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date.
	Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability.
	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		30-Jun-14
		Total		Quoted Prices in	Significant Other	Significant
				Active Markets for	Observable	Unobservable
				Identical Assets	Inputs	Inputs
				(Level 1)	(Level 2)	(Level 3)
	Warrant liability	$	274,000	—	—	$	274,000
		31-Dec-13
		Total		Quoted Prices in	Significant Other	Significant
				Active Markets for	Observable	Unobservable
				Identical Assets	Inputs	Inputs
				(Level 1)	(Level 2)	(Level 3)
	Warrant liability	$	594,000	—	—	$	594,000
	The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 9, “Fair Value of Warrants”. Realized and unrealized gains and losses related to the change in fair value of the warrant liability are included in Other income (expense) on the Statement of Operations.
	A table summarizing the activity for the derivative warrant liability which is measured at fair value using Level 3 inputs is presented in Note 9.

Joint_Venture_Agreement

Joint Venture Agreement	6 Months Ended
	Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Joint Venture Agreement	'
	Joint Venture Agreement
	In November 2011, we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). In exchange for our membership interest in the JV, we made an initial capital contribution of $1.0 million in October 2013 (the “Closing Date”). In addition, we issued 10,000 shares of our common stock to Mayo pursuant to our affiliation agreement and recorded an expense of approximately $175,000. We also recorded additional expense of approximately $231,000 during the fourth quarter of 2013 related to shares issued to Mayo in November of 2011 as the JV achieved certain performance milestones
	The agreement also requires aggregate total capital contributions by us of up to an additional $5.0 million over the next two years. We currently anticipate that we will make capital contributions of $1.0 million in the third quarter of 2014 and $2.0 million each on the first and second anniversaries of the closing date, respectively, with the latter two installments subject to the JV’s achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million. Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. The operation of the joint venture may divert management time from operating our business. No assurances can be given that we will be able to fully fund the joint venture agreement, or that, even if funded, the joint venture will ever achieve the research, development and commercial objectives currently contemplated by the parties, such as the discovery and commercialization of new diagnostic tests utilizing next-generation sequencing. If the development efforts of the joint venture do not result in commercially successful tests or services, it will have an adverse effect on our business, financial condition and results of operations.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	John Pappajohn, a member of the Board of Directors and stockholder, had personally guaranteed our revolving line of credit with Wells Fargo Bank through March 31, 2014. As consideration for his guarantee, as well as each of the eight extensions of this facility through March 31, 2014, Mr. Pappajohn received warrants to purchase an aggregate of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Warrants to purchase 440,113 shares of common stock have been exercised by Mr. Pappajohn through June 30, 2014. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 585,645 at $15.00 per share.
	In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at June 30, 2014.
	On January 3, 2014, the board of directors appointed John Pappajohn to serve as the Chairman of the Board, a position previously held by Dr. Raju S.K. Chaganti, effective January 6, 2014. As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the Company's common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock. The options have a term of ten years from the date on which they were granted. The restricted stock and the options each vest in two equal installments on the one year anniversary and the two year anniversary of the date on which Mr. Pappajohn became the Chairman of the Board.
	On May 19, 2006, we issued a convertible promissory note in favor of our then Chairman and founder, Dr. Chaganti, the holder, which obligated us to pay the holder the sum of $100,000, together with interest at the rate of 8.5% per annum, due April 1, 2014. Interest expense totaled $2,400 through April 10, 2013. On April 10, 2013 the note and accrued interest converted into 13,430 shares of common stock at the IPO price of $10.00 per share. Pursuant to a consulting and advisory agreement, Dr. Chaganti also received options to purchase a total of 36,000 shares of common stock at a price of $10.00 per share which vested over a two year period. Total non-cash stock-based compensation recognized under the consulting agreement for each of the six month periods ended June 30, 2014 and 2013 were $0 and $54,650, respectively. Additionally, on September 15, 2010, we entered into a three year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for providing consulting and technical support services. Total expenses for each of the quarterly periods ended June  30, 2014 and 2013 were $15,000. Pursuant to the terms of the renewed consulting agreement, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period of four years. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention. In 2014 we paid Dr. Chaganti $150,000 which was recognized as an expense in fiscal 2013 when three patents were issued.
	In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc., an entity controlled by John Pappajohn, pursuant to which Equity Dynamics, Inc. received a monthly fee of $10,000 plus reimbursement of expenses. The consulting agreement was terminated effective March 31, 2014. Total expenses for the three months ended June 30, 2014 and 2013 were $0 and $30,000, respectively and for the six months ended June 30, 2014 and 2013 were $30,000 and $60,000, respectively. As of June 30, 2014, we owed Equity Dynamics, Inc. $0.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	In the normal course of business, the Company may become involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof is not expected to have a material adverse effect on our financial condition, results of operations, or liquidity.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions for interim reporting as they are prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2013 that are included in our Form 10-K filed with the SEC on March 28, 2014. The consolidated balance sheet as of December 31, 2013, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2014.
Segment Reporting	'
	Segment Reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of developing and selling diagnostic tests.
Liquidity	'
	Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources: (i) cash collections from our customers (ii) cash received from sales of state net operating loss carryforwards, and; (iii) grants from the National Institutes of Health.
Principles of consolidation	'
	Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiary, Cancer Genetics Italia S.r.l (“CGI Italia”). CGI Italia manufactures DNA probes. CGI Italia had approximately $470,000 and $398,000 in total assets at June 30, 2014 and December 31, 2013, respectively, and approximately $96,000 and $44,000 in total revenue for the six months ended June 30, 2014 and 2013, respectively. All significant intercompany account balances and transactions have been eliminated in consolidation.
Use of estimates and assumptions	'
	Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments and assumptions used to value stock options and warrants. Actual results could differ from those estimates.
Risks and uncertainties	'
	Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.
Cash and cash equivalents	'
	Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any significant credit risk on our cash and cash equivalents.
Restricted cash	'
	Restricted cash: Represents cash held at financial institutions which we may not withdraw and which collateralizes certain of our financial commitments. All of our restricted cash is invested in interest bearing certificates of deposit. Our restricted cash collateralizes a fully-utilized $6.0 million line of credit with Wells Fargo Bank and a $300,000 letter of credit in favor of our landlord, pursuant to the terms of the lease for our Rutherford facility.
Revenue recognition	'
	Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For direct bill customers (including clinical trials customers), revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize revenues once reimbursement experience can be established. Until then, we recognize revenue equal to the amount of cash received. Sales of probes are recorded on the shipping date. We do not bill customers for shipping and handling fees and do not collect any sales or other taxes.
	Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants become contractually due.
Accounts receivable	'
	Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received. For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
Deferred revenue	'
	Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the services are performed.
Fixed assets	'
	Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the consolidated statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a result of events or circumstances, we may be required to record an impairment loss.
Loan guarantee and financing fees	'
	Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective interest method over the term of the related debt.
Warrant liability	'
	Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with the assumptions as follows. The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of our shares. (See Note 9). Following the IPO in April 2013 and until our shares listed on the NASDAQ Capital Market in August 2013, we used the closing price of our shares on the OTC Bulletin Board. Following the listing of our shares on the NASDAQ Capital Market in August 2013, we used the closing price on the NASDAQ Capital Market.
	We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income (loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
Income taxes	'
	Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and research and development credits.
	Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on our deferred tax assets.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated balance sheets and we have not recognized interest and/or penalties in the consolidated statements of operations.
Patents	'
	Patents: We account for intangible assets under ASC 350-30. Patents consist of legal fees incurred and are recorded at cost and amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there were no intangible asset impairments during the periods reported. Accumulated amortization of patents as of June 30, 2014 and December 31, 2013 was approximately $69,000 and $56,000, respectively.
Research and development	'
	Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are expensed as they are incurred.
Registration payment arrangements	'
	Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of June 30, 2014 and December 31, 2013, we have an accrued liability of $300,000 related to the issuance of Series B preferred stock.
Stock-based compensation	'
	Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 7.
	All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued.
	We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
Fair value of financial instruments	'
	Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their estimated fair values due to the short term maturities of those financial instruments. These financial instruments are considered Level 1 measurements under the fair value hierarchy. The fair values of our notes payable, line of credit and capital leases approximate carrying value under Level 2 of the fair value hierarchy. The fair value of warrants recorded as derivative liabilities is described in Note 9.
Joint venture accounted for under the equity method	'
	Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was approximately $298,000 and $0 for the three months ended June 30, 2014 and 2013, respectively and $310,000 and $0 for the six months ended June 30, 2014 and 2013, respectively, and is included in Research and development expense on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $0 and $24,000 at June 30, 2014 and December 31, 2013, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 11.
Subsequent events	'
	Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
Recent accounting pronouncements	'
	Recent Accounting Pronouncements: In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for the Company in the first quarter of fiscal year 2017.  The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on the consolidated financial statements.
Earnings (loss) per share	'
	Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common shares outstanding during the period using the treasury stock method.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data	'
	Basic net loss and diluted net loss per share data were computed as follows:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014				2013			2014			2013
	Numerator:
	Net income (loss) for basic earnings per share	$	(4,186,704	)		$	(9,142,191	)	$	(6,672,597	)	$	(6,781,788	)
	Change in fair value of warrant liability	239,000				—			195,000			5,129,000
	Net (loss) for diluted earnings per share	$	(4,425,704	)		$	(9,142,191	)	$	(6,867,597	)	$	(11,910,788	)
	Denominator:
	Weighted-average basic common shares outstanding	9,302,737				3,985,663			9,289,624			2,667,799
	Assumed conversion of dilutive securities:
	Common stock purchase warrants	15,897				—			24,531			—
	Potentially dilutive common shares	15,897				—			24,531			—
	Denominator for diluted earnings per share – adjusted weighted-average shares	9,318,634				3,985,663			9,314,155			2,667,799
	Basic net income (loss) per share	$	(0.45	)		$	(2.29	)	$	(0.72	)	$	(2.54	)
	Diluted net loss per share	$	(0.47	)		$	(2.29	)	$	(0.74	)	$	(4.46	)
Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation	'
	The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014		2013
	Common stock purchase warrants	1,661,696			1,926,477			1,661,696		1,926,477
	Stock options	1,277,947			507,610			1,277,947		507,610
	Restricted shares of common stock	122,500			—			122,500		—
		3,062,143			2,434,087			3,062,143		2,434,087

Revenue_and_Accounts_Receivabl1

Revenue and Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Schedule of Revenue by Payor Type	'
	Revenue by payor type for the three and six months ended June 30, 2014 and 2013 is comprised of the following:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014	2013
	Medicare	$	268,171		$	151,052		518,292	408,115
	Direct bill (including clinical trials)	850,740			1,226,852			1,719,998	1,738,199
	Insurance carrier and all others	392,759			453,745			703,755	904,002
		$	1,511,670		$	1,831,649		2,942,045	3,050,316
Schedule of Accounts Receivable by Payor Type	'
	Accounts receivable by payor type at June 30, 2014 and December 31, 2013 consists of the following:
		June 30,			December 31,
		2014			2013
	Medicare	$	616,417		$	408,856
	Direct bill (including clinical trials)	863,732			628,830
	Insurance carrier and all others	612,117			565,353
	Allowance for doubtful accounts	(36,000		)	(36,000		)
		$	2,056,266		$	1,567,039

Notes_Payable_and_Line_of_Cred1

Notes Payable and Line of Credit (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Summary of Short-Term and Long-Term Debt Obligations	'
	Below is a summary of our short-term and long-term debt obligations as of June 30, 2014 and December 31, 2013:
		June 30,		December 31,
		2014		2013
	Secured Note Payable, short-term	$	—	$	22,298
	Notes Payable, Current Portion	$	—	$	22,298
	Line of Credit, Principal Balance	$	—	$	6,000,000
	Line of Credit, Current Portion	$	—	$	6,000,000
	Lines of Credit, Long-Term	$	6,000,000	$	—

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Employee and Nonemployee Stock Option Activity	'
	A summary of employee and nonemployee stock option activity for year ended December 31, 2013 and the six months ended June 30, 2014 is as follows:
		Options Outstanding						Weighted-		Aggregate
								Average		Intrinsic
								Remaining		Value
								Contractual
		Number of		Weighted-				Term (in years)
		Shares		Average
				Exercise
				Price
	Outstanding January 1, 2013	553,340		$	12.76			7.13		$	1,142,432
	Granted	426,762		14.57
	Exercised	(164	)	10
	Cancelled or expired	(106,396	)	20.46
	Outstanding December 31, 2013	873,542		$	10.83			7.75		$	3,138,539
	Granted	465,000		15.09
	Exercised	(29,442	)	6.65
	Cancelled or expired	(31,153	)	9.34
	Outstanding June 30, 2014	1,277,947		$	12.52			7.94		$	1,563,786
	Exercisable June 30, 2014	457,489		$	8.46			5.46		$	1,485,305
Summary of Outstanding and Vested Stock Options Granted	'
	The following table summarizes information about outstanding and vested stock options granted to employees and non-employees as of June 30, 2014 as follows:
		Options Outstanding								Options Vested and Exercisable
	Exercise Price	Number of		Weighted-				Weighted-		Number of		Weighted-
		Shares		Average				Average		Shares		Average
		Outstanding		Exercise				Remaining				Exercise Price
				Price				Contract
								Life (in
								Years)
	4	145,000		$	4			4.72		145,000		$	4
	4.8	31,555		4.8				5.56		28,207		4.8
	10	276,180		10				5.65		227,330		10
	11.70 - 11.75	80,600		11.71				9.83		1,306		11.75
	12.50 - 14.18	118,700		13.86				9.51		1,140		12.54
	15.39	335,912		15.39				9.01		37,506		15.39
	15.89	200,000		15.89				9.56		12,500		15.89
	17.38	90,000		17.38				9.72		4,500		17.38
	Total	1,277,947		$	12.52			7.94		457,489		$	8.46
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	'
	The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014		2013			2014		2013
	Volatility	71.6	%	76.21	%		72.13	%	76.04	%
	Risk free interest rate	2.53	%	1.23	%		2.63	%	1.24	%
	Dividend yield	0	%	0	%		0	%	0	%
	Term (years)	9.28		7.46			9.4		7.58
Effects of Stock-Based Compensation Related to Stock Option Awards	'
	The following table presents the effects of stock-based compensation related to stock option awards to employees and nonemployees on our Statement of Operations during the periods presented:
		Three Months Ended June 30,							Six Months Ended June 30,
		2014			2013				2014			2013
	Cost of revenues	$	20,496		$	11,967			$	40,908		$	14,179
	Research and development	143,069			35,962				157,171			90,798
	General and administrative	552,713			94,112				1,021,568			152,267
	Sales and marketing	47,304			30,693				74,058			32,625
	Total stock-based compensation	$	763,582		$	172,734			$	1,293,705		$	289,869

Warrants_Tables

Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Summary of Warrant Activity	'
	The following table summarizes the warrant activity for the six months ended June 30, 2014:
	Issued With / For	Exercise			Warrants	2014 Warrants Exercised		Warrants Outstanding June 30, 2014
		Price			Outstanding
					January 1,
					2014
	Non-Derivative Warrants:
	Financing	$	10		243,334	—		243,334
	Financing	15			436,079	—		436,079
	Debt Guarantee	4			174,288	(44,288	)	130,000
	Debt Guarantee	10			237,500	—		237,500
	Debt Guarantee	15			585,645	—		585,645
	Consulting	10			29,138	—		29,138
		12.38		C	1,705,984	(44,288	)	1,661,696
	Derivative Warrants:
	Financing	10		B	60,000	—		60,000
	Debt Guarantee	10		A	12,500	(12,500	)	—
	Series B Pref. Stock	10		B	18,430	(3,415	)	15,015
	Consulting	10		B	200	—		200
		10		C	91,130	(15,915	)	75,215
		$	12.28	C	1,797,114	(60,203	)	1,736,911
	A	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 9.
	B	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 9.
	C	Weighted average exercise prices are as of June 30, 2014.

Fair_Value_of_Warrants_Tables

Fair Value of Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Assumptions Used in Computing Fair Value of Derivative Warrants	'
	Issued with Debt Guarantee	Exercised During the Six Months Ended June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	10		$	10		$	13.56
	Expected life (years)	0.6			0.83			2.42
	Expected volatility	49.01		%	57.33		%	66.37		%
	Risk-free interest rate	0.08		%	0.13		%	0.32		%
	Expected dividend yield	—		%	—		%	—		%
	Issued with Series B Preferred Shares	Exercised During the Six Months Ended June 30, 2014			As of June 30, 2014			As of December 31, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.72			1.42			1.92
	Expected volatility	46.6		%	48.5		%	59.26		%
	Risk-free interest rate	0.33		%	0.11		%	0.38		%
	Expected dividend yield	—		%	—		%	—		%
	Issued for Consulting	As of June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	10		$	10		$	10
	Expected life (years)	1.65			2.14			2.33
	Expected volatility	47.04		%	63.63		%	63.2		%
	Risk-free interest rate	0.44		%	0.38		%	0.27		%
	Expected dividend yield	—		%	—		%	—		%
	Issued with Financing	Exercised During the Three Months Ended June 30, 2014			As of June 30, 2014			As of December 31, 2013			IPO Date April 5, 2013
	Exercise Price	$	13.34		$	10		$	10		$	13.21
	Expected life (years)	9.78			1.75			2.25			8.3
	Expected volatility	74.7		%	47.05		%	64.4		%	73.22		%
	Risk-free interest rate	1.95		%	0.44		%	0.38		%	1.44		%
	Expected dividend yield	—		%	—		%	—		%	—		%
Summary of Derivative Warrant Activity	'
	The following table summarizes the derivative warrant activity subject to fair value accounting for the six months ended June 30, 2014:
	Issued with/for	Fair value of			Fair value			Change in			Fair value of
		warrants			of warrants			fair value			warrants
		outstanding as of			exercised			of warrants			outstanding as of
		December 31, 2013									30-Jun-14
	Series B Preferred Stock	$	117,000		$	(38,000	)	$	(28,000	)	$	51,000
	Debt Guarantee	64,000			(87,000		)	23,000			—
	Consulting	1,000			—			—			1,000
	Financing	412,000			—			(190,000		)	222,000
		$	594,000		$	(125,000	)	$	(195,000	)	$	274,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:
		30-Jun-14
		Total		Quoted Prices in	Significant Other	Significant
				Active Markets for	Observable	Unobservable
				Identical Assets	Inputs	Inputs
				(Level 1)	(Level 2)	(Level 3)
	Warrant liability	$	274,000	—	—	$	274,000
		31-Dec-13
		Total		Quoted Prices in	Significant Other	Significant
				Active Markets for	Observable	Unobservable
				Identical Assets	Inputs	Inputs
				(Level 1)	(Level 2)	(Level 3)
	Warrant liability	$	594,000	—	—	$	594,000

Description_of_Business_Basis_1

Description of Business, Basis of Presentation, Pending Acquisition, Public Offerings and Reverse Stock Splits - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Mar. 01, 2013

Feb. 08, 2013

Jun. 30, 2014

Dec. 31, 2013

Oct. 31, 2013

Apr. 10, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

12-May-14

Jul. 16, 2014

Jul. 31, 2014

Jul. 16, 2014

Jul. 16, 2014

Jul. 16, 2014

Jul. 16, 2014

IPO [Member]

India Agreement [Member]

US Agreement [Member]

Other Assets [Member]

BioServe [Member]

BioServe [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

employee

agreement

Gentris Corporation [Member]

Gentris Corporation [Member]

Gentris Corporation [Member]

Gentris Corporation [Member]

Gentris Corporation [Member]

Gentris Corporation [Member]

employee

Common Stock [Member]

Minimum [Member]

Maximum [Member]

sqft

clinical_trial

Acquisition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of clinical trials

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

Number of employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39

'

'

'

Square feet of laboratory space

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,000

'

'

'

Acquisition price, cash

'

'

'

'

'

'

'

'

'

'

'

'

$3,250,000

'

'

'

'

'

Business Combination, Acquisition Related Costs

'

'

'

'

'

'

'

'

'

'

'

'

147,500

'

'

'

'

'

Payments of Merger Related Costs, Financing Activities

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

'

'

'

'

Notes Receivable, Related Parties

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

Loan Receivable, Interest Rate, Stated Percentage

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition price, equity issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

Potential earn-out

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

Potential earn-out, minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

Potential earn-out revenue, minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,750,000

'

Potential earn-out revenue, maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,550,000

Weighted average share price (usd per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10.15

'

'

Number of shares issued in acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

147,843

'

'

Pending Acquisition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of acquisition agreement

'

'

'

'

'

'

'

'

'

'

12-May-14

'

'

'

'

'

'

'

Number of agreements

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Number of employees

'

'

'

'

'

'

'

'

'

'

26

'

'

'

'

'

'

'

Aggregate ownership percentage

'

'

'

'

'

'

'

74.00%

15.00%

'

'

'

'

'

'

'

'

'

Aggregate purchase price payable

'

'

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash value of common stock, Shares

'

'

'

'

'

'

'

84,278

'

'

'

'

'

'

'

'

'

'

Public offering common stock period

'

'

'30 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash payable

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued (in shares)

'

'

9,464,709

9,275,384

10,000

690,000

'

'

8,687

'

'

'

'

'

'

'

'

'

Assume indebtedness

'

'

'

'

'

'

'

'

$170,000

'

'

'

'

'

'

'

'

'

Number of shares vested

'

'

22,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock in public offerings description

'

'

'

'

'

'

'common stock in public offerings in August 2013 and in October 2013

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

0.4

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jan. 31, 2014

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

segment

Cancer Genetics Italia SRL [Member]

Cancer Genetics Italia SRL [Member]

Cancer Genetics Italia SRL [Member]

Other Assets [Member]

Other Assets [Member]

Research and Development [Member]

Research and Development [Member]

Research and Development [Member]

Research and Development [Member]

Wells Fargo Bank [Member]

Patents [Member]

Patents [Member]

NEW JERSEY

NEW JERSEY

Minimum [Member]

Maximum [Member]

Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segment

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets

$49,599,422

'

$49,599,422

'

$55,157,273

$470,000

'

$398,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Total revenue

1,511,670

1,831,649

2,942,045

3,050,316

'

96,000

44,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit, outstanding amount

6,000,000

'

6,000,000

'

0

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

Letter of credit amount held as collateral for lease

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed assets, estimated useful lives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'7 years

Accrual for interest or penalties

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net operating loss carryforward

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,301,643

8,018,107

'

'

Proceeds from sale of operating loss carryforward

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,813,941

663,900

'

'

Intangible asset impairments

'

'

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated amortization of patents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

69,000

56,000

'

'

'

'

Accrued liability related to the issuance of Series B preferred stock

300,000

'

300,000

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss in equity-method investment

'

'

-310,193

0

'

'

'

'

'

'

298,000

0

310,000

0

'

'

'

'

'

'

'

Net receivable due from the joint venture

'

'

'

'

'

'

'

'

$0

$24,000

'

'

'

'

'

'

'

'

'

'

'

Significant_Accounting_Policie4

Significant Accounting Policies - Computation of Basic Net Income (Loss) and Diluted Net Loss per Share Data (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net income (loss)	($4,186,704)	($9,142,191)	($6,672,597)	($6,781,788)
Change in fair value of warrant liability	239,000	0	195,000	5,129,000
Net (loss) for diluted earnings per share	($4,425,704)	($9,142,191)	($6,867,597)	($11,910,788)
Denominator:	'	'	'	'
Weighted-average basic common shares outstanding (in shares)	9,302,737	3,985,663	9,289,624	2,667,799
Assumed conversion of dilutive securities:	'	'	'	'
Common stock purchase warrants (in shares)	15,897	0	24,531	0
Potentially dilutive common shares (in shares)	15,897	0	24,531	0
Denominator for diluted earnings per share - adjusted weighted-average shares (in shares)	9,318,634	3,985,663	9,314,155	2,667,799
Basic net income (loss) per share (usd per share)	($0.45)	($2.29)	($0.72)	($2.54)
Diluted net loss per share (usd per share)	($0.47)	($2.29)	($0.74)	($4.46)

Significant_Accounting_Policie5

Significant Accounting Policies - Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Securities excluded from calculation (in shares)	3,062,143	2,434,087	3,062,143	2,434,087
Common Stock Purchase Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Securities excluded from calculation (in shares)	1,661,696	1,926,477	1,661,696	1,926,477
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Securities excluded from calculation (in shares)	1,277,947	507,610	1,277,947	507,610
Restricted Shares of Common Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Securities excluded from calculation (in shares)	122,500	0	122,500	0

Revenue_and_Accounts_Receivabl2

Revenue and Accounts Receivable - Schedule of Revenue by Payor Type (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'	'
Revenue	$1,511,670	$1,831,649	$2,942,045	$3,050,316
Medicare [Member]	'	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'	'
Revenue	268,171	151,052	518,292	408,115
Direct bill (including clinical trials clients) [Member]	'	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'	'
Revenue	850,740	1,226,852	1,719,998	1,738,199
Insurance carrier and all others [Member]	'	'	'	'
Health Care Organization, Receivable and Revenue Disclosures [Line Items]	'	'	'	'
Revenue	$392,759	$453,745	$703,755	$904,002

Revenue_and_Accounts_Receivabl3

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Payor Type (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for doubtful accounts	($36,000)	($36,000)
Accounts receivable, net	2,056,266	1,567,039
Medicare [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	616,417	408,856
Direct bill (including clinical trials clients) [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	863,732	628,830
Insurance carrier and all others [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$612,117	$565,353

Revenue_and_Accounts_Receivabl4

Revenue and Accounts Receivable - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Sites accounted for approximately 10% or more of our revenue	1	1	1	1
Sales [Member] | Clinical Testing [Member]	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Percentage of revenue	51.00%	74.00%	57.00%	69.00%
Sales [Member] | Community Hospitals [Member]	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Percentage of revenue	44.00%	23.00%	38.00%	27.00%
Sales [Member] | Community Hospitals [Member] | 10% or More Clinical Revenue [Member]	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Percentage of revenue	10.00%	10.00%	10.00%	10.00%
Sales [Member] | Clinical Trial Client [Member] | 10% or More Clinical Revenue [Member]	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'
Percentage of revenue	23.00%	50.00%	28.00%	38.00%

Notes_Payable_and_Line_of_Cred2

Notes Payable and Line of Credit - Summary of Short-Term and Long-Term Debt Obligations (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Notes payable, Current Portion	$0	$22,298
Line of Credit, Principal Balance	0	6,000,000
Line of Credit, Current Portion	0	6,000,000
Lines of Credit, Long-Term	6,000,000	0
Secured Note Payable [Member]	'	'
Debt Instrument [Line Items]	'	'
Notes payable, Current Portion	$0	$22,298

Notes_Payable_and_Line_of_Cred3

Notes Payable and Line of Credit - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	6 Months Ended			0 Months Ended
	Apr. 01, 2014	Mar. 31, 2014	Jun. 30, 2014	Apr. 01, 2014	Dec. 31, 2013	Sep. 25, 2012	Dec. 31, 2013	Sep. 25, 2012
	Wells Fargo Bank [Member]	Wells Fargo Bank [Member]	Wells Fargo Bank [Member]	Wells Fargo Bank [Member]	Wells Fargo Bank [Member]	Secured Note Payable [Member]	Secured Note Payable [Member]	Secured Note Payable [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Borrowings from utilization of line of credit	'	'	$6,000,000	'	$6,000,000	'	'	'
Debt instrument spread on variable rate	1.75%	'	1.75%	'	'	'	'	'
Interest on line of credit at end period	'	2.00%	'	'	'	'	'	'
Debt instrument maturity date	1-Apr-16	'	'	'	'	25-Mar-14	'	'
Credit agreement, Entered date	'	1-Apr-14	'	'	'	'	'	'
Interest rate at period end	'	'	'	2.00%	'	'	'	'
Restricted cash required as collateral	'	'	6,000,000	'	'	'	'	'
Secured note interest	'	'	'	'	'	'	'	18.00%
Secured note outstanding	'	'	'	'	'	'	$22,298	'

Letter_of_Credit_Additional_In

Letter of Credit - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Letter of credit facility restricted amount	$50,000
Stand-by letter of credit	$300,000

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

Apr. 10, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Oct. 31, 2013

Apr. 10, 2013

Apr. 10, 2013

Apr. 10, 2013

Apr. 10, 2013

Aug. 19, 2013

Sep. 05, 2013

Aug. 19, 2013

Oct. 28, 2013

Oct. 28, 2013

Cleveland Clinic [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Secondary Offering [Member]

Secondary Offering [Member]

Secondary Offering [Member]

Follow-On Offering [Member]

Follow-On Offering [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued (in shares)

'

9,464,709

'

9,275,384

10,000

690,000

2,000

'

'

'

'

1,500,000

'

3,286,700

Underwriter's overallotment shares

'

'

'

'

'

90,000

'

'

'

'

'

'

'

428,700

Common stock sold at IPO, price per share

'

'

'

'

'

$10

'

'

'

'

'

$10

'

$14

Gross proceeds from public offering

$6,900,000

'

'

'

'

'

'

'

'

$15,000,000

'

'

$46,000,000

'

Net proceeds from initial public offering

5,000,000

0

5,054,514

'

'

'

'

'

'

'

'

'

'

'

Value of debt converted

9,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of debt into common stock

963,430

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares converted to common stock

'

'

'

'

'

'

'

376,525

910,800

'

'

'

'

'

Reclassification of derivative warrants

7,200,000

0

7,170,000

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from secondary public offering

'

'

'

'

'

'

'

'

'

13,300,000

'

'

42,300,000

'

Amount used for repayment of certain indebtedness

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

Additional common stock sold at public offering

'

'

'

'

'

'

'

'

'

'

105,000

'

'

'

Gross proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

Additional net proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

$947,000

'

'

'

Preferred stock, shares authorized

'

9,764,000

'

9,764,000

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Apr. 05, 2013

Jun. 30, 2014

Dec. 31, 2013

Apr. 05, 2013

Apr. 05, 2013

Oct. 31, 2013

Apr. 30, 2013

Jun. 30, 2014

Dec. 31, 2010

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2011

Jun. 30, 2014

Apr. 01, 2010

Apr. 29, 2008

Apr. 30, 2013

Dec. 31, 2010

Apr. 30, 2013

stock_plan

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Employees [Member]

2011 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2008 Stock Option Plan [Member]

2008 Stock Option Plan [Member]

2008 Stock Option Plan [Member]

Strike Price of $25.00 or More [Member]

Strike Price of $25.00 or More [Member]

Strike Price of $12.50 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of equity incentive plans

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock shares authorized for issuance

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

Shares of common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

350,000

'

550,000

251,475

'

'

'

Options granted maximum exercisable period

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of shares under Stock Options Plans

'

48,000

'

'

'

'

'

'

80,000

'

'

'

'

'

'

'

'

'

Shares available for future awards

'

'

'

'

'

'

'

'

'

'

1,099,688

'

30,059

'

'

'

'

'

Restricted stock awarded under Stock Option Plans

'

122,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock appreciation rights

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options strike price

'

'

'

'

'

'

$25

'

'

'

'

'

'

'

'

'

$25

$12.50

Exchange options for number of options held with exercise price equal to initial public offering price, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

'

80.00%

Price per share on equity offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

$10

Outstanding stock options

'

1,277,947

'

336,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering exercisable lower price range

$12.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering exercisable upper price range

$33.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial offering, options exchanged

242,070

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price option

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Approved options issued

53,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options issued, exercise price

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of common stock

'

$11.30

$13.78

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested stock options granted

'

'

'

'

'

'

'

$1,383,611

'

$6,196,957

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)

'

'

'

'

'

'

'

'3 years 6 months

'

'3 years 6 months 4 days

'

'

'

'

'

'

'

'

Options exchanged

'

29,442

164

'

48,000

10,000

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options exchanged

'

'

'

'

$10

$15.39

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_Summary_of_

Stock Option Plans - Summary of Employee and Nonemployee Stock Option Activity (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Options Outstanding, Number of Shares Outstanding	'	'	'
Outstanding, beginning balance	873,542	553,340	'
Granted	465,000	426,762	'
Exercised	-29,442	-164	'
Cancelled or expired	-31,153	-106,396	'
Outstanding, ending balance	1,277,947	873,542	553,340
Exercisable	457,489	'	'
Options Outstanding, Weighted-Average Exercise Price	'	'	'
Outstanding, beginning balance	$10.83	$12.76	'
Granted	$15.09	$14.57	'
Exercised	$6.65	$10	'
Cancelled or expired	$9.34	$20.46	'
Outstanding, ending balance	$12.52	$10.83	$12.76
Exercisable	$8.46	'	'
Weighted-Average Remaining Contractual Term (in years)	'	'	'
Outstanding	'7 years 11 months 9 days	'7 years 9 months	'7 years 1 month 17 days
Exercisable	'5 years 5 months 16 days	'	'
Aggregate Intrinsic Value	'	'	'
Outstanding, beginning balance	$3,138,539	$1,142,432	'
Outstanding, ending balance	1,563,786	3,138,539	1,142,432
Exercisable	$1,485,305	'	'

Stock_Option_Plans_Summary_of_1

Stock Option Plans - Summary of Outstanding and Vested Stock Options Granted (Detail) (USD $)	0 Months Ended	6 Months Ended
	Apr. 05, 2013	Jun. 30, 2014	Apr. 05, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	$12.50	'	'
Exercise price range, upper range limit	$33.80	'	'
Number of Shares, Options Outstanding	'	1,277,947	336,300
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$12.52	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'7 years 11 months 9 days	'
Number of Shares, Options Vested and Exercisable	'	457,489	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$8.46	'
Exercise Price 4.00 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$4	'
Exercise price range, upper range limit	'	$4	'
Number of Shares, Options Outstanding	'	145,000	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$4	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'4 years 8 months 19 days	'
Number of Shares, Options Vested and Exercisable	'	145,000	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$4	'
Exercise Price 4.80 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$4.80	'
Exercise price range, upper range limit	'	$4.80	'
Number of Shares, Options Outstanding	'	31,555	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$4.80	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'5 years 6 months 22 days	'
Number of Shares, Options Vested and Exercisable	'	28,207	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$4.80	'
Exercise Price 10.00 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$10	'
Exercise price range, upper range limit	'	$10	'
Number of Shares, Options Outstanding	'	276,180	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$10	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'5 years 7 months 24 days	'
Number of Shares, Options Vested and Exercisable	'	227,330	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$10	'
Exercise Price Range 11.70 - 11.75 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$11.70	'
Exercise price range, upper range limit	'	$11.75	'
Number of Shares, Options Outstanding	'	80,600	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$11.71	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 9 months 29 days	'
Number of Shares, Options Vested and Exercisable	'	1,306	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$11.75	'
Exercise Price Range 12.50 - 14.18 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$12.50	'
Exercise price range, upper range limit	'	$14.18	'
Number of Shares, Options Outstanding	'	118,700	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$13.86	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 6 months 4 days	'
Number of Shares, Options Vested and Exercisable	'	1,140	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$12.54	'
Exercise Price 15.39 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$15.39	'
Exercise price range, upper range limit	'	$15.39	'
Number of Shares, Options Outstanding	'	335,912	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$15.39	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 4 days	'
Number of Shares, Options Vested and Exercisable	'	37,506	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$15.39	'
Exercise Price 15.89 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$15.89	'
Exercise price range, upper range limit	'	$15.89	'
Number of Shares, Options Outstanding	'	200,000	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$15.89	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 6 months 22 days	'
Number of Shares, Options Vested and Exercisable	'	12,500	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$15.89	'
Exercise Price 17.38 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit	'	$17.38	'
Exercise price range, upper range limit	'	$17.38	'
Number of Shares, Options Outstanding	'	90,000	'
Weighted-Average Exercise Price, Options Outstanding (usd per share)	'	$17.38	'
Weighted-Average Remaining Contractual Life, Options Outstanding (in years)	'	'9 years 8 months 18 days	'
Number of Shares, Options Vested and Exercisable	'	4,500	'
Weighted-Average Exercise Price, Options Vested and Exercisable (usd per share)	'	$17.38	'

Stock_Option_Plans_WeightedAve

Stock Option Plans - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Detail) (Non-Employees [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Non-Employees [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Volatility	71.60%	76.21%	72.13%	76.04%
Risk free interest rate	2.53%	1.23%	2.63%	1.24%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Term (years)	'9 years 3 months 11 days	'7 years 5 months 16 days	'9 years 4 months 24 days	'7 years 6 months 29 days

Stock_Option_Plans_Effects_of_

Stock Option Plans - Effects of Stock-Based Compensation Related to Stock Option Awards (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation	$763,582	$172,734	$1,293,705	$289,869
Cost of Revenues [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation	20,496	11,967	40,908	14,179
Research and Development [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation	143,069	35,962	157,171	90,798
General and Administrative [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation	552,713	94,112	1,021,568	152,267
Sales and Marketing [Member]	'	'	'	'
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'
Total stock-based compensation	$47,304	$30,693	$74,058	$32,625

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	1 Months Ended				6 Months Ended		1 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Jul. 31, 2014
							Subsequent Event [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Proceeds form warrants exercised	$177,154	'	'	$950	$178,102	$96,000	'
Warrants exercised to purchase common stock	44,288	12,500	3,320	95	'	'	130,000
Common stock per share value on warrant exercised	$4	$10	$10	$10	$4	'	$4
Warrants, surrendered	'	7,230	1,661	'	'	'	45,894
Warrants issued	'	5,270	1,659	'	'	'	84,106

Warrants_Summary_of_Warrant_Ac

Warrants - Summary of Warrant Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$12.28	[1]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	1,797,114
Warrants Exercised (in shares)	-60,203
Warrants Outstanding, Ending Balance (in shares)	1,736,911
Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$12.38	[1]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	1,705,984
Warrants Exercised (in shares)	-44,288
Warrants Outstanding, Ending Balance (in shares)	1,661,696
Warrant Issued For [Member] | Warrant Derivative [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10	[1]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	91,130
Warrants Exercised (in shares)	-15,915
Warrants Outstanding, Ending Balance (in shares)	75,215
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$4
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	174,288
Warrants Exercised (in shares)	-44,288
Warrants Outstanding, Ending Balance (in shares)	130,000
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	237,500
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	237,500
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$15
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	585,645
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	585,645
Debt Guarantee [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10	[2]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	12,500
Warrants Exercised (in shares)	-12,500
Warrants Outstanding, Ending Balance (in shares)	0
Series B Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10	[3]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	18,430
Warrants Exercised (in shares)	-3,415
Warrants Outstanding, Ending Balance (in shares)	15,015
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	243,334
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	243,334
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$15
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	436,079
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	436,079
Consulting [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	29,138
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	29,138
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10	[3]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	60,000
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	60,000
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants, Exercise Price (usd per share)	$10	[3]
Class of Warrants Outstanding [Roll Forward]	'
Warrants Outstanding, Beginning Balance (in shares)	200
Warrants Exercised (in shares)	0
Warrants Outstanding, Ending Balance (in shares)	200
[1]	Weighted average exercise prices are as of JuneB 30, 2014.
[2]	These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note 9.
[3]	These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 9.

Fair_Value_of_Warrants_Assumpt

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Detail) (USD $)	0 Months Ended		6 Months Ended	0 Months Ended		6 Months Ended	0 Months Ended		1 Months Ended	0 Months Ended			3 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Apr. 05, 2013	Jun. 30, 2014	Dec. 31, 2013	Apr. 05, 2013	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Apr. 05, 2013	Jun. 30, 2014
	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]	Debt Guarantee [Member]	Consulting [Member]	Consulting [Member]	Consulting [Member]	Financing [Member]	Financing [Member]	Financing [Member]	Financing [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'
Exercise Price	$10	$10	$10	$10	$13.56	$10	$10	$10	$10	$10	$10	$13.21	$13.34
Expected life (years)	'1 year 5 months 1 day	'1 year 11 months 1 day	'1 year 8 months 19 days	'9 months 29 days	'2 years 5 months 1 day	'7 months 6 days	'2 years 1 month 21 days	'2 years 3 months 29 days	'1 year 7 months 24 days	'1 year 9 months	'2 years 3 months	'8 years 3 months 18 days	'9 years 9 months 11 days
Expected volatility	48.50%	59.26%	46.60%	57.33%	66.37%	49.01%	63.63%	63.20%	47.04%	47.05%	64.40%	73.22%	74.70%
Risk-free interest rate	0.11%	0.38%	0.33%	0.13%	0.32%	0.08%	0.38%	0.27%	0.44%	0.44%	0.38%	1.44%	1.95%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Fair_Value_of_Warrants_Additio

Fair Value of Warrants - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'	'
Fair value of warrants issue price	$11.30	$13.78
Minimum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Fair value of stock prices in computing fair value for warrants exercised	$15.20	'
Fair value of stock prices in computing fair value for warrants issued	$9.60	'
Maximum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Fair value of stock prices in computing fair value for warrants exercised	$19.86	'
Fair value of stock prices in computing fair value for warrants issued	$9.96	'

Fair_Value_of_Warrants_Summary

Fair Value of Warrants - Summary of Derivative Warrant Activity (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Class of Warrants Outstanding [Roll Forward]	'	'	'	'
Beginning balance	'	'	$594,000	'
Fair value of warrants exercised	'	'	-125,000	'
Change in fair value of warrant liability	-239,000	170,000	-195,000	-5,129,000
Ending balance	274,000	'	274,000	'
Debt Guarantee [Member]	'	'	'	'
Class of Warrants Outstanding [Roll Forward]	'	'	'	'
Beginning balance	'	'	64,000	'
Fair value of warrants exercised	'	'	-87,000	'
Change in fair value of warrant liability	'	'	23,000	'
Ending balance	0	'	0	'
Consulting [Member]	'	'	'	'
Class of Warrants Outstanding [Roll Forward]	'	'	'	'
Beginning balance	'	'	1,000	'
Fair value of warrants exercised	'	'	0	'
Change in fair value of warrant liability	'	'	0	'
Ending balance	1,000	'	1,000	'
Financing [Member]	'	'	'	'
Class of Warrants Outstanding [Roll Forward]	'	'	'	'
Beginning balance	'	'	412,000	'
Fair value of warrants exercised	'	'	0	'
Change in fair value of warrant liability	'	'	-190,000	'
Ending balance	222,000	'	222,000	'
Series B Preferred Stock [Member]	'	'	'	'
Class of Warrants Outstanding [Roll Forward]	'	'	'	'
Beginning balance	'	'	117,000	'
Fair value of warrants exercised	'	'	-38,000	'
Change in fair value of warrant liability	'	'	-28,000	'
Ending balance	$51,000	'	$51,000	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$274,000	$594,000
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$274,000	$594,000

Joint_Venture_Agreement_Additi

Joint Venture Agreement - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended			1 Months Ended			6 Months Ended	1 Months Ended		3 Months Ended
	Oct. 31, 2013	Dec. 31, 2013	Jun. 30, 2014	Apr. 10, 2013	Oct. 31, 2013	Nov. 30, 2011	Jun. 30, 2014	Jun. 30, 2014	Oct. 31, 2015	Oct. 31, 2014	Sep. 30, 2014
					Joint Venture Agreement [Member]	Joint Venture Agreement [Member]	Joint Venture Agreement [Member]	Joint Venture Agreement [Member]	Joint Venture Agreement [Member]	Joint Venture Agreement [Member]	Joint Venture Agreement [Member]
								Maximum [Member]	Scenario, Forecast [Member]	Scenario, Forecast [Member]	Scenario, Forecast [Member]
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Entered into agreement date	'	'	'	'	'	30-Nov-11	'	'	'	'	'
Percentage of outstanding membership interests in joint venture	'	'	'	'	'	'	50.00%	'	'	'	'
Capital contribution in exchange of membership interests	'	'	'	'	$1,000,000	'	'	$5,000,000	$2,000,000	$2,000,000	$1,000,000
Common stock, shares issued (in shares)	10,000	9,275,384	9,464,709	690,000	'	'	'	'	'	'	'
Additional expense related to shares issued	175,000	231,000	'	'	'	'	'	'	'	'	'
Fair value of capital contribution in joint venture	'	'	'	'	'	'	$6,000,000	'	'	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

Sep. 15, 2010

Mar. 31, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 31, 2013

Apr. 10, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 03, 2014

Apr. 10, 2013

Jun. 30, 2014

Jun. 30, 2013

Apr. 10, 2013

Jun. 30, 2014

Jun. 30, 2014

Aug. 31, 2010

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 03, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jan. 03, 2014

extension

Financial Guarantee [Member]

Financial Guarantee [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

John Pappajohn [Member]

Chairman of the Board [Member]

Chairman of the Board [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Dr. Chaganti [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Equity Dynamics, Inc. [Member]

Compensation for Serving as Chairman of Board [Member]

Compensation for Serving as Chairman of Board [Member]

Consulting and Advisory Agreement [Member]

Consulting and Advisory Agreement [Member]

Restricted Stock [Member]

Financial Guarantee [Member]

Financial Guarantee [Member]

IPO [Member]

2011 Equity Plan [Member]

patent

patent

2011 Equity Plan [Member]

Chairman of the Board [Member]

Chairman of the Board [Member]

Chairman of the Board [Member]

installment

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of revolving line of credit extensions facility

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock purchased

'

'

'

'

'

'

'

284,000

202,630

'

1,051,506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock exercised (in shares)

'

'

60,203

'

'

'

440,113

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants adjusted in conjunction with IPO

'

'

'

'

'

'

'

'

436,079

585,645

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding per share

'

'

'

'

'

'

'

'

$15

$15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional amount of loan received

'

'

'

'

'

'

'

'

$6,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible shares issued to common stock

'

'

9,464,709

9,275,384

10,000

690,000

'

'

'

'

'

675,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price of notes

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement with related party, description of required payment

'

'

'As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the Company's common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention.

'

'

'

'

'

'

'

'

'

'

'

Compensation for serving as chairman of the board

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

Shares granted

'

'

465,000

426,762

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

Effective appointment date

'

'

'

'

'

'

'

'

'

'

'

'

6-Jan-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Number of installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Options term and vesting period description

'

'

'The options have a term of ten years from the date on which they were granted. The restricted stock and the options each vest in two equal installments on the one year anniversary and the two year anniversary of the date on which Mr. Pappajohn became the Chairman of the Board.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes issued to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate due to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

'

'

'

'

'

'

'

'

'

Interest expenses on notes issued to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,400

'

'

'

'

'

'

'

'

'

'

'

'

Convertible common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,430

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock conversion price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,000

'

'

Common stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

Common stock, vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

Consulting and advisory agreement expenses under stock option plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

54,650

'

Consulting agreement period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting and advisory services fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

Agreement with related party, consulting fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

15,000

'

'

'

'

0

30,000

30,000

60,000

'

'

'

'

'

Common stock, shares purchased price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.89

'

'

'

'

'

'

'

'

'

'

Agreement with related party, one-time payment required

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

Agreement with related party, percentage of net revenues required to be paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

Patents expense paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

Number of patents were issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

3

'

'

'

'

'

'

'

'

'

'

'

Agreement with related party, fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

Due to related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

$0

'

'

'

'

'

'